Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Closed 12-29 16:00:00 EST

304.58

+35.63

+13.25%

盘后301.00

-3.58-1.18%

19:59 EST

High317.72	Low298.00	Vol1.60M
Open317.72	D1 Closing268.95	Amplitude7.33%
Mkt Cap7.62B	Tradable Cap6.03B	Total Shares25.01M
T/O490.08M	T/O Rate8.11%	Tradable Shares19.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":304.58,"timestamp":1767042000000,"preClose":268.95,"halted":0,"volume":1604966,"hourTrading":{"tag":"盘后","latestPrice":301,"preClose":304.58,"latestTime":"19:59 EST","volume":557251,"amount":170213600.5987,"timestamp":1767056384212},"delay":0,"floatShares":19790700,"shares":25007171,"eps":-12.922727,"marketStatus":"Closed","change":35.63,"latestTime":"12-29 16:00:00 EST","open":317.72,"high":317.72,"low":298,"amount":490081471.89188004,"amplitude":0.073322,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.922727,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1767085200000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":268.95,"preHourTrading":{"tag":"盘前","latestPrice":318,"preClose":268.95,"latestTime":"09:29 EST","volume":11992,"amount":3606239.0368,"timestamp":1767018599908},"postHourTrading":{"tag":"盘后","latestPrice":301,"preClose":304.58,"latestTime":"19:59 EST","volume":557251,"amount":170213600.5987,"timestamp":1767056384212},"volumeRatio":3.37461,"impliedVol":0.7127,"impliedVolPercentile":0.028},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"2595730205","title":"Praxis Precision Heading for 'Exciting' 2026, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2595730205","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595730205?lang=en_us&edition=fundamental","pubTime":"2025-12-30 04:23","pubTimestamp":1767039812,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines  is set for \"exciting\" 2026 after securing a Breakthrough Therapy Designation for ulixacaltamide in essential tremor, Truist Securities said in a note Monday.The note said securing the label is a positive \"surprise\" because there is an approved drug for essential tremor, propranolol.\"Therefore, to be granted BTD despite the availability of a commercial drug...implies high unmet need in ET and at least some perception of ulixa's superiority,\" the report said.The label is typically granted during earlier stages of drug development, the note said. For ulixa to obtain it after trial results imply that the FDA decision may have been based, at least in part, on the positive trial results, it added.The report also pointed to indication of FDA's \"comfort\" with the data and pre-new drug application meeting.\"All of the above de-risk forthcoming NDA submission in early 2026,\" the note said. Truist kept its high conviction buy rating.Price: 302.97, Change: +34.02, Percen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","PRAX","BK4139"],"gpt_icon":0},{"id":"2595734049","title":"Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2595734049","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595734049?lang=en_us&edition=fundamental","pubTime":"2025-12-30 01:23","pubTimestamp":1767028980,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/12/49615360/praxis-stock-surges-on-fda-breakthrough-status-for-essential-tremor-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/12/49615360/praxis-stock-surges-on-fda-breakthrough-status-for-essential-tremor-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4581","BK4139","LU0889565916.HKD","BK4144","BK4585","BK4590","LU0320765992.SGD","LU0109394709.USD","ET","PRAX","BK4588","BK4561"],"gpt_icon":0},{"id":"2595739210","title":"Praxis Shares Rise on Ulixacaltamide Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2595739210","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595739210?lang=en_us&edition=fundamental","pubTime":"2025-12-29 23:42","pubTimestamp":1767022920,"startTime":"0","endTime":"0","summary":"Shares of Praxis Precision Medicines rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor.Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control.Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program.The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026.Praxis shares were recently changing hands at $300.74, up nearly 13%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","PRAX","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2595273642","title":"Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2595273642","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595273642?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:48","pubTimestamp":1767019680,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.\nConsidering buying PRAX stock? Here’s what analysts think: \nRead This Next: \nPhoto via Shutterstock","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/Side-View-Of-Concentrated-Crypto-Trader-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/Side-View-Of-Concentrated-Crypto-Trader-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/12/49609941/praxis-precision-medicines-to-rally-more-than-213-here-are-8-top-analyst-forecasts-for-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/12/49609941/praxis-precision-medicines-to-rally-more-than-213-here-are-8-top-analyst-forecasts-for-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4139","PRAX","LU0889565916.HKD"],"gpt_icon":0},{"id":"2595733915","title":"BUZZ-U.S. STOCKS ON THE MOVE-Vail Resorts, Tonix, Praxis Precision, AXT","url":"https://stock-news.laohu8.com/highlight/detail?id=2595733915","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595733915?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:57","pubTimestamp":1767016675,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Vail Resorts, Tonix, Praxis Precision, AXTEikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nL4N3XZ0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345781412.USD","BK4216","LU0788108826.HKD","LU1023059493.AUD","SG9999001143.SGD","BK4233","BK4122","BK4205","BK4135","LU0368265764.SGD","LU0979878070.USD","BK4220","LU0612318385.USD","LU0496367417.USD","BK4532","LU0266512127.USD","LU0345780281.USD","LU1430597077.USD","LU0055631609.USD","LU1223082519.USD","BK4096","MTN","PRAX","LU1223082196.USD","BK4588","LU1242518857.USD","LU1280957306.USD","LU0266512473.USD","LU1242518931.SGD","BK4147","LU0498741890.SGD","LU0889565916.HKD","TNXP","AXTI","LU0109394709.USD","LU0630314457.HKD","LU0345780950.USD","LU0498741114.HKD","LU0300736062.USD","LU0654597011.USD","BK4583","LU0320765992.SGD","BK4548","LU0330918003.SGD","LU0612318971.USD","LU2498475776.HKD","BK4139","BK4533","LU0724618789.USD","LU1223083913.SGD","LU0456854461.SGD","BK4099","BK4017","LU0278409577.USD","LU0300736492.USD","LU0640476718.USD","LU1883866441.USD","BK4570","LU2462611646.USD","BK4210","BK4547","BK4124","BK4585","LU0345780521.USD","BK4160","LU0075056555.USD","LU0788109121.HKD"],"gpt_icon":0},{"id":"2595336497","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2595336497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595336497?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:55","pubTimestamp":1767016531,"startTime":"0","endTime":"0","summary":"Health care stocks were steady premarket Monday, with the State Street Health Care Select Sector SPDR ETF  slightly advancing and the iShares Biotechnology ETF  unchanged.Praxis Precision Medicines  shares were up more than 11% after the company said the US Food and Drug Administration has granted Breakthrough Therapy Designation for ulixacaltamide to treat patients with Essential Tremor disorder.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","IBB","LU0109394709.USD","LU0320765992.SGD","PRAX","BK4585","BK4139","LABU","XBI","LU0889565916.HKD","XLV","BK4588"],"gpt_icon":0},{"id":"2595738625","title":"BUZZ-Praxis Precision climbs after FDA's 'breakthrough' tag for tremor drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738625","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738625?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:25","pubTimestamp":1767014731,"startTime":"0","endTime":"0","summary":"BUZZ-Praxis Precision climbs after FDA's 'breakthrough' tag for tremor drug** Shares of drug developer Praxis Precision Medicines PRAX.O rise 11.5% to $299.9 premarket** PRAX says U.S. Food and Drug Administration has granted \"breakthrough\" tag for its experimental drug, ulixacaltamide, to treat patients with essential tremor** The breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or those with unmet medical need** Essential tremor is a neurological movement disorder that causes involuntary, rhythmic shaking in hands, arms, head or voice** As of last close, stock has more than tripled YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nL4N3XZ0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","PRAX"],"gpt_icon":0},{"id":"2595780263","title":"FDA Grants Breakthrough Therapy Designation to Praxis Precision Medicines' Ulixacaltamide for Essential Tremor","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780263","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780263?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013212,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has announced that the U.S. Food and Drug Administration  has granted Breakthrough Therapy Designation to ulixacaltamide, its selective small molecule inhibitor of T-type calcium channels, for the treatment of essential tremor. The designation was based on positive topline results from the Essential3 Phase 3 program. Following a successful pre-NDA meeting and alignment with the FDA on the New Drug Application  content, Praxis expects to submit the NDA for ulixacaltamide in early 2026. The Breakthrough Therapy Designation is intended to expedite the development and review of drugs that may offer substantial improvement over existing therapies for serious conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL3mrK7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0109394709.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014021.USD","PRAX","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","BK4588","LU2210149790.SGD","NDAQ","LU2095319765.USD","LU0889565916.HKD","IE00BKPKM429.USD","LU0320765992.SGD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2595780456","title":"Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide Hcl in Essential Tremor","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780456?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA50KLBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","PRAX","LU0109394709.USD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2595678048","title":"Praxis Precision Medicines Inc - to Submit Ulixacaltamide Nda in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2595678048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595678048?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA50KLBQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","PRAX","LU0889565916.HKD","BK4139","LU0109394709.USD"],"gpt_icon":0},{"id":"2595780917","title":"U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780917?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:58","pubTimestamp":1767013115,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio Dec 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Expedia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nL4N3XZ0LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","BK4585","BK4142","BP","EXPE","LU0109394709.USD","IE00BFMHRM44.USD","LU2065169927.USD","FOLD","LU2065171402.SGD","PRAX","BK4588","LU2065171311.SGD","HAS","BK4216","LU0320765646.SGD","LU2065170008.USD","LU0072461881.USD","LU0320765992.SGD","BK4139","LU1829250122.USD","MTN","BK4007","BK4190","LU0054578231.USD","LU1162221912.USD","LU0889565916.HKD","BK4566","LU0162691827.USD","PALI"],"gpt_icon":0},{"id":"2595849297","title":"Praxis Precision Medicines Inc : Btig Raises Target Price to $843 From $507","url":"https://stock-news.laohu8.com/highlight/detail?id=2595849297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595849297?lang=en_us&edition=fundamental","pubTime":"2025-12-29 19:08","pubTimestamp":1767006482,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XY03F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","PRAX","LU0109394709.USD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2595781023","title":"Praxis Precision Med Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2595781023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595781023?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:52","pubTimestamp":1767005520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2025 05:52 ET (10:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","PRAX"],"gpt_icon":0},{"id":"2593123204","title":"FDA-Endorsed Elsunersen Trial Redesign Could Be A Game Changer For Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593123204","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593123204?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:16","pubTimestamp":1766499408,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines recently completed a Type C meeting with the FDA, securing agreement to convert its EMBRAVE3 trial of elsunersen for early-onset SCN2A developmental and epileptic encephalopathy into a smaller, single-arm, baseline-controlled study focused on seizure reduction over 24 weeks plus an open-label extension.\nThis shift, alongside prior orphan and rare pediatric designations, underscores elsunersen’s potential as a disease-modifying therapy in an ultra-rare, genetically...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/fda-endorsed-elsunersen-trial-redesign-could-be-a-game-chang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/fda-endorsed-elsunersen-trial-redesign-could-be-a-game-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","LU0109394709.USD","PRAX","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"2592514331","title":"Praxis Precision Medicines (PRAX) Valuation After FDA-Backed EMBRAVE3 Redesign for Elsunersen","url":"https://stock-news.laohu8.com/highlight/detail?id=2592514331","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592514331?lang=en_us&edition=fundamental","pubTime":"2025-12-20 17:12","pubTimestamp":1766221949,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) just cleared a key regulatory hurdle, wrapping up a Type C meeting with the FDA that reshapes its EMBRAVE3 trial for elsunersen into a leaner single arm design.\nSee our latest analysis for Praxis Precision Medicines.\nThe news around EMBRAVE3 lands on top of a powerful run, with Praxis delivering a roughly 44 percent 1 month share price return and a staggering 546 percent 3 month share price return, while its 1 year total shareholder return above 250 percent...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-valuation-after-fda-backed-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-valuation-after-fda-backed-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","LU0109394709.USD","LU0889565916.HKD","PRAX","LU0320765992.SGD"],"gpt_icon":0},{"id":"2591564783","title":"Oppenheimer Adjusts Praxis Precision Medicines PT to $750 From $250, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591564783","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591564783?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:46","pubTimestamp":1765809998,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $419.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","PRAX","OPY"],"gpt_icon":0},{"id":"2590509891","title":"Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590509891","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590509891?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:57","pubTimestamp":1765544265,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $385.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DB","PRAX"],"gpt_icon":0},{"id":"2590415325","title":"Praxis Precision Medicines - to File a Nda for Relutrigine in Scn2a and Scn8a Dees in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590415325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590415325?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:24","pubTimestamp":1765488298,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH1BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRAX","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2590150145","title":"Praxis Precision Medicines Reports Relutrigine Shows Significant Seizure Reduction in EMBOLD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590150145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590150145?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458039,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. announced plans to file a New Drug Application  for relutrigine in early 2026, following successful discussions with the FDA. The application will be based on efficacy and safety data from the EMBOLD study, which demonstrated that relutrigine provided statistically significant and clinically meaningful improvements in children with SCN2A and SCN8A developmental and epileptic encephalopathies . The company reported that relutrigine showed robust, short- and long-term improvements in motor seizures and maintained seizure freedom in some patients, alongside a favorable safety profile. These results have already been collected and discussed with the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1Pk1v4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","PRAX","SG9999014039.USD","LU0109394709.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0889565916.HKD","BK4139","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","LU0320765992.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210150020.SGD","BK4585","BK4588"],"gpt_icon":0},{"id":"2590166035","title":"Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590166035","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590166035?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203828/0/en/Praxis-Precision-Medicines-Announces-Plans-to-File-an-NDA-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies-in-Early-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","LU0889565916.HKD","BK4200","ODD","LU0109394709.USD","LU0320765992.SGD","BK4139","CNS","PRAX","IE0009354923.USD","ASO","BK4183","BK4135"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":-0.0145},{"period":"1month","weight":0.4265},{"period":"3month","weight":4.1287},{"period":"6month","weight":5.2547},{"period":"1year","weight":2.4384},{"period":"ytd","weight":2.4947}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0156},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1226},{"period":"1year","weight":0.148},{"period":"ytd","weight":0.1778}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.344924},{"month":2,"riseRate":0.2,"avgChangeRate":-0.21435},{"month":3,"riseRate":0.2,"avgChangeRate":-0.183614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.018417},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.184746}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction